Last reviewed 2026-05-30 · How we verify

Warner Chilcott LLC Sarafem Tablets

Torrent Pharmaceuticals Limited · Phase 1 active Small molecule ✓ Verified May 2026

Warner Chilcott LLC Sarafem Tablets is a Small molecule drug developed by Torrent Pharmaceuticals Limited. It is currently in Phase 1 development.

Warner Chilcott LLC's Sarafem Tablets are a formulation of the medication fluoxetine, which is used to treat various conditions. According to ClinicalTrials.gov, Sarafem Tablets have been studied in a bioequivalence trial with Torrent's Fluoxetine Tablets in healthy subjects.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Warner Chilcott LLC Sarafem Tablets
Sponsor	Torrent Pharmaceuticals Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Warner Chilcott LLC Sarafem Tablets CI brief — competitive landscape report
Warner Chilcott LLC Sarafem Tablets updates RSS · CI watch RSS
Torrent Pharmaceuticals Limited portfolio CI

Frequently asked questions about Warner Chilcott LLC Sarafem Tablets

What is Warner Chilcott LLC Sarafem Tablets?

Warner Chilcott LLC Sarafem Tablets is a Small molecule drug developed by Torrent Pharmaceuticals Limited.

Who makes Warner Chilcott LLC Sarafem Tablets?

Warner Chilcott LLC Sarafem Tablets is developed by Torrent Pharmaceuticals Limited (see full Torrent Pharmaceuticals Limited pipeline at /company/torrent-pharmaceuticals-limited).

What development phase is Warner Chilcott LLC Sarafem Tablets in?

Warner Chilcott LLC Sarafem Tablets is in Phase 1.

Manufacturer: Torrent Pharmaceuticals Limited — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing